Research Article
Year 2025,
Volume: 16 Issue: 2, 240 - 245, 10.04.2025
Abstract
References
- 1- Jemal, A., Siegel, R., Xu, J, et al. Cancer statistics.CA a cancer journal for clinicians. 2010; 60(5), 277:300. DOI: 10.3322/caac.20073
- 2- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2), 69:90. DOI: 10.3322/caac.20107.
- 3- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2. CA Cancer J Clin. 2009;59(4), 225:49. DOI: 10.3322/caac.20006.
- 4- Kocabeyoğlu Ö. Helicobacter pylori infeksiyonlarının epidemiyolojisi, patogenezi ve laboratuar tanısı. Klinik Derg 1992; 5:11-4.
- 5- Gönüllü g, Çakar B, Arslan F, et al. Epirubicin, cisplatin and continuous infusion 5-flourouracil (ECF) in unresectable or metastatic gastric cancer: Asingle institution experience. Turkish Journal of Cancer 2006; 36(4):176-81.
- 6- Roth A, Kolaric K, Zupanc D, et al. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study. Tumori. 1999; 85(4):234-8. DOI: 10.1177/030089169908500404.
- 7- Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; Nov 1;24(31):4991-7. DOI: 10.1200/JCO.2006.06.8429.
- 8- Yalcin S. Gastric cancer in Turkey-a bridge between west and east. Gastrointest Cancer Res 2009;3(1):29-32.
- 9- Theuer CP, de Virgilio C, Keese G, et al. Gastric Adenocarcinoma in patients 40 years of age or younger. Am J Surg 1996;172(5):473-6.
- 10- Türkdoğan MK, Akman N, Tuncer İ, et al. Epidemiological aspects of endemic upper gastrointestinal cancers in Eastern Turkey. Hepato-Gastroenterology. 2010; 52:496-500)
- 11- Tuncer İ, Uygan İ, Kösem M, et al. Van ve Çevresinde Görülen Üst Gastrointestinal Sistem Kanserlerinin Demografik ve Histopatolojik Özellikleri. Van Tıp Dergisi. 2010; 8;1.
- 12- Tünger Ö. Helicobacter pylori infeksiyonları. İnfeks Derg. 2008; 22:107-15.
- 13- Yılmaz Ö, Okcu N. Helicobacter pylori ve gastrointestinal sistemle ilişkili hastalıklar. AÜTD. 2006; 38:13-7.
- 14- Khatami, F., & Karbakhsh, M. Socioeconomic position and incidence of gastric cancer: a systematic review and meta-analysis. Journal of epidemiology and community health, 2015; 69(8), 818–819. https://doi.org/10.1136/jech-2013-203784
- 15- Brennan MF, Karpeh MS Jr. Surgery for gastric cancer: the American view. Semin Oncol. 1996;23(3):352-9.
- 16- Landry J, Tepper JE, Wood WC, et al. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys. 1990;19(6):1357-62.
- 17- Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. 2002;88(1):21-7.
- 18- Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725-30.
- 19- Lee, J. H., Kim, M. G., Jung, M. S., et al. Prognostic significance of lymphovascular invasion in node-negative gastric cancer. World journal of surgery, 2015; 39(3), 732–739. https://doi.org/10.1007/s00268-014-2846-y
- 20- Wu, C. Y., Wu, M. S., et al. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. Journal of clinical oncology: American Society of Clinical Oncology, 2010; 28(18), 2952–2957. https://doi.org/10.1200/JCO.2009.26.0695
- 21- Mukoyama T, Kanaji S, Sawada R, et al. Safety and Efficacy of Neoadjuvant Chemotherapy for Advanced Gastric Cancer in Elderly Patients. Anticancer Res. 2023; Dec;43(12): 5649-5656.DOI: 10.21873/anticanres.16769.
- 22- Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017; Aug 29;8(8):CD004064. DOI: 10.1002/14651858.CD004064.pub4.
Year 2025,
Volume: 16 Issue: 2, 240 - 245, 10.04.2025
Abstract
Background/Purpose: The aim of our study was to examine the factors that affect the prognosis of gastric cancer and to evaluate the effect of different chemotherapy regimens on disease-free survival and overall survival.
Methods: This cohort study retrospectively analyzed patients diagnosed with gastric cancer at our institution between 2009 and 2013. The demographic characteristics of the patients, the presence of Helicobacter pylori (HP), and the disease-free and overall survival according to the patients' treatment protocols were examined.
Results: Thirty-three women and 85 men with a mean age of 58.6 ± 10.3 years were included in this study. %41 of the patients received 5-fluouracil, leukoverine chemotherapy (MAYO regimen), 26.2% docetaxel, cisplatin and fluorouracil combination (DCF regimen), 10.7% Epirubicin, cisplatin and Fluorouracil (ECF regimen), and 6.6% Cisplatin-Xeloda regimen. The average disease-free survival was 14.7 ± 11.1 months, and overall survival time was 16.5 ± 11.4 months. Disease-free survival and overall survival were longer in the MAYO regimen group compared to the combination chemotherapy groups (p <0.001). On multivariate analysis, metastasis and TNM stage were independent negative prognostic factors for disease-free and overall survival.
Conclusion: Our study showed that disease-free and overall survival rates are quite low in advanced tumors and in patients with metastases at diagnosis, and revealed the limited effect of chemotherapy protocols, especially in this group of patients. However, the Mayo regimen was superior to other treatment protocols.
Keywords
References
- 1- Jemal, A., Siegel, R., Xu, J, et al. Cancer statistics.CA a cancer journal for clinicians. 2010; 60(5), 277:300. DOI: 10.3322/caac.20073
- 2- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2), 69:90. DOI: 10.3322/caac.20107.
- 3- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2. CA Cancer J Clin. 2009;59(4), 225:49. DOI: 10.3322/caac.20006.
- 4- Kocabeyoğlu Ö. Helicobacter pylori infeksiyonlarının epidemiyolojisi, patogenezi ve laboratuar tanısı. Klinik Derg 1992; 5:11-4.
- 5- Gönüllü g, Çakar B, Arslan F, et al. Epirubicin, cisplatin and continuous infusion 5-flourouracil (ECF) in unresectable or metastatic gastric cancer: Asingle institution experience. Turkish Journal of Cancer 2006; 36(4):176-81.
- 6- Roth A, Kolaric K, Zupanc D, et al. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study. Tumori. 1999; 85(4):234-8. DOI: 10.1177/030089169908500404.
- 7- Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; Nov 1;24(31):4991-7. DOI: 10.1200/JCO.2006.06.8429.
- 8- Yalcin S. Gastric cancer in Turkey-a bridge between west and east. Gastrointest Cancer Res 2009;3(1):29-32.
- 9- Theuer CP, de Virgilio C, Keese G, et al. Gastric Adenocarcinoma in patients 40 years of age or younger. Am J Surg 1996;172(5):473-6.
- 10- Türkdoğan MK, Akman N, Tuncer İ, et al. Epidemiological aspects of endemic upper gastrointestinal cancers in Eastern Turkey. Hepato-Gastroenterology. 2010; 52:496-500)
- 11- Tuncer İ, Uygan İ, Kösem M, et al. Van ve Çevresinde Görülen Üst Gastrointestinal Sistem Kanserlerinin Demografik ve Histopatolojik Özellikleri. Van Tıp Dergisi. 2010; 8;1.
- 12- Tünger Ö. Helicobacter pylori infeksiyonları. İnfeks Derg. 2008; 22:107-15.
- 13- Yılmaz Ö, Okcu N. Helicobacter pylori ve gastrointestinal sistemle ilişkili hastalıklar. AÜTD. 2006; 38:13-7.
- 14- Khatami, F., & Karbakhsh, M. Socioeconomic position and incidence of gastric cancer: a systematic review and meta-analysis. Journal of epidemiology and community health, 2015; 69(8), 818–819. https://doi.org/10.1136/jech-2013-203784
- 15- Brennan MF, Karpeh MS Jr. Surgery for gastric cancer: the American view. Semin Oncol. 1996;23(3):352-9.
- 16- Landry J, Tepper JE, Wood WC, et al. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys. 1990;19(6):1357-62.
- 17- Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. 2002;88(1):21-7.
- 18- Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725-30.
- 19- Lee, J. H., Kim, M. G., Jung, M. S., et al. Prognostic significance of lymphovascular invasion in node-negative gastric cancer. World journal of surgery, 2015; 39(3), 732–739. https://doi.org/10.1007/s00268-014-2846-y
- 20- Wu, C. Y., Wu, M. S., et al. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. Journal of clinical oncology: American Society of Clinical Oncology, 2010; 28(18), 2952–2957. https://doi.org/10.1200/JCO.2009.26.0695
- 21- Mukoyama T, Kanaji S, Sawada R, et al. Safety and Efficacy of Neoadjuvant Chemotherapy for Advanced Gastric Cancer in Elderly Patients. Anticancer Res. 2023; Dec;43(12): 5649-5656.DOI: 10.21873/anticanres.16769.
- 22- Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017; Aug 29;8(8):CD004064. DOI: 10.1002/14651858.CD004064.pub4.
There are 22 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Research Articles |
| Authors | |
| Publication Date | April 10, 2025 |
| Submission Date | August 9, 2024 |
| Acceptance Date | December 27, 2024 |
| Published in Issue | Year 2025Volume: 16 Issue: 2 |
